Urogen Pharma’s (URGN) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Urogen Pharma (NASDAQ:URGN) in a report published on Monday,Benzinga reports. They currently have a $33.00 target price on the stock.

Several other research firms also recently issued reports on URGN. Wall Street Zen raised Urogen Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday, January 21st. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Urogen Pharma currently has a consensus rating of “Moderate Buy” and an average target price of $33.29.

Urogen Pharma Stock Up 7.1%

URGN stock opened at $20.16 on Monday. Urogen Pharma has a twelve month low of $3.42 and a twelve month high of $30.00. The firm has a market cap of $981.39 million, a price-to-earnings ratio of -6.30 and a beta of 1.34. The business’s fifty day simple moving average is $21.03 and its two-hundred day simple moving average is $20.87.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.12. The business had revenue of $37.84 million during the quarter, compared to the consensus estimate of $39.92 million. Research analysts expect that Urogen Pharma will post -3.12 EPS for the current year.

Insider Transactions at Urogen Pharma

In related news, General Counsel Jason Drew Smith sold 7,479 shares of the stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total value of $147,261.51. Following the transaction, the general counsel owned 51,326 shares of the company’s stock, valued at $1,010,608.94. This represents a 12.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Mark Schoenberg sold 7,373 shares of the company’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total transaction of $145,174.37. Following the completion of the transaction, the insider owned 144,985 shares of the company’s stock, valued at approximately $2,854,754.65. The trade was a 4.84% decrease in their position. The disclosure for this sale is available in the SEC filing. 4.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Urogen Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of URGN. Osaic Holdings Inc. boosted its holdings in Urogen Pharma by 491.2% during the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after buying an additional 3,070 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Urogen Pharma by 27.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after acquiring an additional 486 shares during the period. State of Wyoming purchased a new stake in shares of Urogen Pharma during the 3rd quarter worth approximately $66,000. Russell Investments Group Ltd. boosted its stake in shares of Urogen Pharma by 1,594.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after acquiring an additional 3,125 shares in the last quarter. Finally, Strs Ohio acquired a new stake in shares of Urogen Pharma in the 3rd quarter worth approximately $76,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.